ADHD - Alcobra Ltd. - Ordinary Shares

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
10.22
+0.42 (+4.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.80
Open1.40
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.40 - 1.64
52 Week Range1.40 - 1.64
Volume1,107,893
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press4 months ago

    Alcobra reports 3Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 9 cents. The company's shares closed at $1.35. A year ago, they were trading at $1.91. _____ This story was generated by Automated ...

  • PR Newswire4 months ago

    Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

    SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus's LUNAR™ lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement ...

  • Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?
    Simply Wall St.5 months ago

    Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?

    If you are looking to invest in Alcobra Ltd’s (NASDAQ:ADHD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Associated Press6 months ago

    Alcobra reports 2Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 13 cents. The company's shares closed at $1.03. A year ago, they were trading at $4.91. _____ This story was generated by ...

  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zacks7 months ago

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

  • New Strong Buy Stocks for July 20th
    Zacks7 months ago

    New Strong Buy Stocks for July 20th

    New Strong Buy Stocks for July 20th

  • Accesswire8 months ago

    Featured Company News - Gilead's Vosevi Receives Positive Opinion from European CHMP; Set to Deliver Advanced Treatment for All HCV Genotypes

    Research Desk Line-up: Alcobra Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Gilead Sciences, ...

  • Reuters8 months ago

    Shire wins U.S. approval for long-acting ADHD drug

    Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The U.S. Food and Drug Administration (FDA) green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin-based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the overnight FDA news.

  • Reuters9 months ago

    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial. ADHD is a chronic condition characterized by hyperactivity, impulsive behavior and a difficulty in sustaining focus. NLS' drug, mazindol, is a non-stimulant, but trial data showed it could be as effective as a stimulant.

  • Associated Press9 months ago

    Alcobra reports 1Q loss

    The Tel Aviv, Israel-based company said it had a loss of 13 cents per share. The company's shares closed at $1.13. A year ago, they were trading at $5.12. _____ This story was generated by Automated Insights ...

  • GuruFocus.com9 months ago

    Chuck Royce Continues to Buy These 10 Stocks

    Guru increased these holdings in the last 2 quarters